269 related articles for article (PubMed ID: 28719234)
1. The In Vivo Effects of the CB
Cairns EA; Szczesniak AM; Straiker AJ; Kulkarni PM; Pertwee RG; Thakur GA; Baldridge WH; Kelly MEM
J Ocul Pharmacol Ther; 2017 Oct; 33(8):582-590. PubMed ID: 28719234
[TBL] [Abstract][Full Text] [Related]
2. Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action.
Oltmanns MH; Samudre SS; Castillo IG; Hosseini A; Lichtman AH; Allen RC; Lattanzio FA; Williams PB
J Ocul Pharmacol Ther; 2008 Feb; 24(1):104-15. PubMed ID: 18201139
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure.
Garai S; Schaffer PC; Laprairie RB; Janero DR; Pertwee RG; Straiker A; Thakur GA
Bioorg Med Chem; 2021 Nov; 50():116421. PubMed ID: 34634617
[TBL] [Abstract][Full Text] [Related]
4. Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.
Thapa D; Cairns EA; Szczesniak AM; Kulkarni PM; Straiker AJ; Thakur GA; Kelly MEM
Molecules; 2020 Jan; 25(2):. PubMed ID: 31968549
[TBL] [Abstract][Full Text] [Related]
5. Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure.
Szczesniak AM; Maor Y; Robertson H; Hung O; Kelly ME
J Ocul Pharmacol Ther; 2011 Oct; 27(5):427-35. PubMed ID: 21770780
[TBL] [Abstract][Full Text] [Related]
6. Enantiomer-specific positive allosteric modulation of CB
Mitjavila J; Yin D; Kulkarni PM; Zanato C; Thakur GA; Ross R; Greig I; Mackie K; Straiker A
Pharmacol Res; 2018 Mar; 129():475-481. PubMed ID: 29158048
[TBL] [Abstract][Full Text] [Related]
7. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.
Slivicki RA; Xu Z; Kulkarni PM; Pertwee RG; Mackie K; Thakur GA; Hohmann AG
Biol Psychiatry; 2018 Nov; 84(10):722-733. PubMed ID: 28823711
[TBL] [Abstract][Full Text] [Related]
8. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
Laprairie RB; Bagher AM; Rourke JL; Zrein A; Cairns EA; Kelly MEM; Sinal CJ; Kulkarni PM; Thakur GA; Denovan-Wright EM
Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
[TBL] [Abstract][Full Text] [Related]
9. Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
Laprairie RB; Kulkarni PM; Deschamps JR; Kelly MEM; Janero DR; Cascio MG; Stevenson LA; Pertwee RG; Kenakin TP; Denovan-Wright EM; Thakur GA
ACS Chem Neurosci; 2017 Jun; 8(6):1188-1203. PubMed ID: 28103441
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid receptor 1 positive allosteric modulator (GAT229) attenuates cisplatin-induced neuropathic pain in mice.
Bagher AM; Binmahfouz LS; Shaik RA; Eid BG
Saudi Pharm J; 2023 Feb; 31(2):255-264. PubMed ID: 36942271
[TBL] [Abstract][Full Text] [Related]
11. Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists.
Hudson BD; Beazley M; Szczesniak AM; Straiker A; Kelly ME
J Pharmacol Exp Ther; 2011 Dec; 339(3):757-67. PubMed ID: 21885619
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of topical CB1 agonist WIN 55212-2 on retinal ganglion cells after acute rise in intraocular pressure induced ischemia in rat.
Pinar-Sueiro S; Zorrilla Hurtado JÁ; Veiga-Crespo P; Sharma SC; Vecino E
Exp Eye Res; 2013 May; 110():55-8. PubMed ID: 23454099
[TBL] [Abstract][Full Text] [Related]
13. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2.
Song ZH; Slowey CA
J Pharmacol Exp Ther; 2000 Jan; 292(1):136-9. PubMed ID: 10604940
[TBL] [Abstract][Full Text] [Related]
14. Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg.
Roebuck AJ; Greba Q; Smolyakova AM; Alaverdashvili M; Marks WN; Garai S; Baglot SL; Petrie G; Cain SM; Snutch TP; Thakur GA; Hill MN; Howland JG; Laprairie RB
Neuropharmacology; 2021 Jun; 190():108553. PubMed ID: 33845076
[TBL] [Abstract][Full Text] [Related]
15. Evidence that cannabinoid CB1 receptors regulate intraocular pressure via two opposing mechanisms.
Miller S; Daily L; Ploss M; Greig I; Ross R; Rayana NP; Dai J; Sugali CK; Mao W; Straiker A
Exp Eye Res; 2020 Nov; 200():108241. PubMed ID: 32941875
[TBL] [Abstract][Full Text] [Related]
16. A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects.
Ignatowska-Jankowska BM; Baillie GL; Kinsey S; Crowe M; Ghosh S; Owens RA; Damaj IM; Poklis J; Wiley JL; Zanda M; Zanato C; Greig IR; Lichtman AH; Ross RA
Neuropsychopharmacology; 2015 Dec; 40(13):2948-59. PubMed ID: 26052038
[TBL] [Abstract][Full Text] [Related]
17. Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.
Cawston EE; Redmond WJ; Breen CM; Grimsey NL; Connor M; Glass M
Br J Pharmacol; 2013 Oct; 170(4):893-907. PubMed ID: 23937487
[TBL] [Abstract][Full Text] [Related]
18. CB
Trexler KR; Eckard ML; Kinsey SG
Pharmacol Biochem Behav; 2019 Feb; 177():27-33. PubMed ID: 30597181
[TBL] [Abstract][Full Text] [Related]
19. Allosteric modulators restore orthosteric agonist binding to mutated CB
Dopart R; Kendall DA
J Pharm Pharmacol; 2020 Jan; 72(1):84-91. PubMed ID: 31722122
[TBL] [Abstract][Full Text] [Related]
20. Insight into the mechanism of action of ORG27569 at the cannabinoid type one receptor utilising a unified mathematical model.
Green HM; Yang L; Zhu X; Finlay DB; Duffull SB; Glass M
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):5105-5118. PubMed ID: 38227196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
